...Alize received exclusive, worldwide rights from New Paradigm Therapeutics to develop and commercialize peptides derived from a fragment... ...a single IGFBP2 peptide up to clinical development and then out-license or divest the program. New Paradigm Therapeutics... ...divestment revenues. Alize set up a newco, Alize Pharma III S.A.S., to develop the peptides. New Paradigm Therapeutics Inc....
...Alize received exclusive, worldwide rights from New Paradigm Therapeutics to develop and commercialize peptides derived from a fragment... ...a single IGFBP2 peptide up to clinical development and then out-license or divest the program. New Paradigm Therapeutics... ...divestment revenues. Alize set up a newco, Alize Pharma III S.A.S., to develop the peptides. New Paradigm Therapeutics Inc....
